Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.65 |
| ▸ | SELP | P16109 | 8/20 | 0.51 |
| ▸ | MAG | P20916 | 5/20 | 0.49 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30654173 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30651267 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30655024 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30651699 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30650616 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30651821 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30655658 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL20455660 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30655151 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30653001 | 1.00 | SIGLEC7 (0.65) | SIGLEC7SELPMAGSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2372 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720480-B1 | PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS | JUNO THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4727571-A2 | ACTIVATION OF T-CELLS WITH MUTANT G-CSFR | Interius Biotherapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724112-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOLOGICAL DISORDERS | Interius Biotherapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4725503-A2 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | University Of Southern California (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724464-A1 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260098074-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2026-04-09 | — | — | US | claimed |
| EP-4720312-A2 | GENE EDITING COMPOSITIONS OF POLYPEPTIDES AND NUCLEIC ACIDS, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260091112-A1 | VACCINE COMPRISING PERIPHERAL BLOOD MONONUCLEAR CELLS LOADED WITH NATURAL KILLER T CELL LIGAND AND ANTIGEN | CELLID CO., LTD. (KR) | 2026-04-02 | — | — | US | claimed |
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | JUNO THERAPEUTICS, INC. (US) | 2026-03-19 | — | — | US | claimed |
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | ANGELES THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20220090132-A1 | CAR T CELL METHODS AND CONSTRUCTS | ABINTUS BIO INC (US) | 2022-03-24 | — | — | US | claimed |
| WO-2022057941-A1 | IMMUNE EFFECTOR CELL EXPRESSING IL-7R BINDING PROTEIN | 克莱格医学有限公司 | 2022-03-24 | — | — | WO | claimed |
| EP-3962519-A1 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED CD247 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS | Juno Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3962520-A1 | CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS | Juno Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022036041-A1 | IMPROVING IMMUNE CELL FUNCTION | KITE PHARMA, INC (US) | 2022-02-17 | — | — | WO | claimed |
| US-20220050114-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | JUNO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | US | claimed |
| US-20220047677-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2022-02-17 | — | — | US | claimed |
| CN-114025788-A | Cells expressing recombinant receptors from modified TGFBR2 loci, related polynucleotides and methods | 朱诺治疗学股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2022025638-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL STABILIZING IMMUNE SYNAPSE | (주)티카로스 | 2022-02-03 | — | — | WO | claimed |
| WO-2022018262-A1 | T-CELLS EXPRESSING IMMUNE CELL ENGAGERS IN ALLOGENIC SETTINGS | CELLECTIS S.A. (FR) | 2022-01-27 | — | — | WO | claimed |